Waters Corporation Q1 EPS $2.70 and $1.27B Revenue Spur UBS to Raise Target to $375
WAT•Waters Corporation posted Q1 earnings of $2.70 per share on revenues of $1.27 billion, its fourth consecutive quarter of beats that lifted its profit forecast. UBS maintained a neutral rating but raised its price target to $375, citing $520 million in revenue from acquired biosciences assets and 11% organic growth.
1. Q1 earnings and revenue beats
Waters Corporation delivered Q1 earnings of $2.70 per share on revenues of $1.27 billion, outperforming consensus for the fourth straight quarter. Strong demand for its laboratory and drug development tools contributed to this sustained outperformance and supported an upward revision to the annual profit outlook.
2. Contribution from acquired unit
The recently acquired Biosciences and Diagnostic Solutions business generated $520 million in Q1 revenue, bolstering overall results. This acquisition integration drove both top-line growth and diversification of the company’s end markets.
3. Analyst rating and outlook update
UBS retained a neutral rating on Waters but raised its price target from $330 to $375, reflecting confidence in the company’s expanded product portfolio and improved margin outlook. The uplift incorporates robust organic growth and the financial impact of recent strategic acquisitions.
